Open the lid on the problems facing global pharmaceutical giant Endo International plc and they start to look familiar. An insolvent US multinational laden with over $8 billion (€7.36 billion) in debt files for Chapter 11 bankruptcy in the Southern District of New York in August 2022.  In the background are thousands of opioid claims against the drugmaker, and antitrust suits too. Add Irish headquarters in Ballsbridge, Dublin, a proposed twin-track US-Irish restructuring process where first-lien creditors effectively take over the business and assets of the pharma group, and it all sounds a little like the Mallinckrodt bailout — another…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .